Michael J. Yang is CCO & VP at ACADIA PHARMACEUTICALS INC (ACAD). They have made 10 open-market trades across 2 companies since 2019, most recently 2026-06-10.
CIK 0001702283
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $26K since 2024, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | BUY | 2024-08-14 | 2024-08-14 | $12.90 | $26K | +13.5% | +2.7% | +31.7% |
| ACAD | SELL | 2021-01-06 | 2021-01-08 | $53.34 | $119K | -2.2% | -3.6% | -61.1% |
| ACAD | SELL | 2020-10-16 | 2020-10-19 | $42.56 | $106K | +14.1% | +29.7% | +28.6% |
| ACAD | SELL | 2020-07-07 | 2020-07-09 | $56.18 | $2.4M | -20.2% | -26.3% | -23.4% |
| ACAD | SELL | 2020-04-30 | 2020-05-01 | $49.21 | $148K | +3.4% | +9.8% | -4.6% |
| ACAD | SELL | 2019-12-12 | 2019-12-13 | $44.46 | $9.4M | -0.4% | -7.6% | -21.8% |
| ACAD | SELL | 2019-12-12 | 2019-12-13 | $44.45 | $4.7M | -0.4% | -7.6% | -21.8% |
| ACAD | SELL | 2019-12-09 | 2019-12-11 | $50.47 | $733K | -1.1% | +0.4% | -9.0% |
| ACAD | SELL | 2019-12-09 | 2019-12-11 | $50.47 | $1.5M | -1.1% | +0.4% | -9.0% |
| ACAD | SELL | 2019-10-15 | 2019-10-17 | $39.65 | $35K | +6.3% | +13.4% | +14.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.